These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21306419)

  • 1. Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.
    Liem-Moolenaar M; de Boer P; Timmers M; Schoemaker RC; van Hasselt JG; Schmidt S; van Gerven JM
    Br J Clin Pharmacol; 2011 Jun; 71(6):886-98. PubMed ID: 21306419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers.
    Ebert U; Grossmann M; Oertel R; Gramatté T; Kirch W
    J Clin Pharmacol; 2001 Jan; 41(1):51-60. PubMed ID: 11144994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.
    Alvarez-Jimenez R; Groeneveld GJ; van Gerven JM; Goulooze SC; Baakman AC; Hay JL; Stevens J
    Br J Clin Pharmacol; 2016 Oct; 82(4):1011-21. PubMed ID: 27273555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids.
    Strougo A; Zuurman L; Roy C; Pinquier JL; van Gerven JM; Cohen AF; Schoemaker RC
    J Psychopharmacol; 2008 Sep; 22(7):717-26. PubMed ID: 18583433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intrapulmonary tetrahydrocannabinol administration in humans.
    Zuurman L; Roy C; Schoemaker RC; Hazekamp A; den Hartigh J; Bender JC; Verpoorte R; Pinquier JL; Cohen AF; van Gerven JM
    J Psychopharmacol; 2008 Sep; 22(7):707-16. PubMed ID: 18515447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
    Klumpers LE; Beumer TL; van Hasselt JG; Lipplaa A; Karger LB; Kleinloog HD; Freijer JI; de Kam ML; van Gerven JM
    Br J Clin Pharmacol; 2012 Jul; 74(1):42-53. PubMed ID: 22680341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.
    Baakman AC; Alvarez-Jimenez R; Rissmann R; Klaassen ES; Stevens J; Goulooze SC; den Burger JCG; Swart EL; van Gerven JMA; Groeneveld GJ
    Br J Clin Pharmacol; 2017 Aug; 83(8):1676-1687. PubMed ID: 28217868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.
    Liem-Moolenaar M; Rad M; Zamuner S; Cohen AF; Lemme F; Franson KL; van Gerven JM; Pich EM
    Br J Clin Pharmacol; 2011 Jun; 71(6):907-16. PubMed ID: 21223356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs.
    Scheinin H; Helminen A; Huhtala S; Grönroos P; Bosch JA; Kuusela T; Kanto J; Kaila T
    Ther Drug Monit; 1999 Apr; 21(2):141-51. PubMed ID: 10217331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications influencing central cholinergic pathways affect fixation stability, saccadic response time and associated eye movement dynamics during a temporally-cued visual reaction time task.
    Naicker P; Anoopkumar-Dukie S; Grant GD; Modenese L; Kavanagh JJ
    Psychopharmacology (Berl); 2017 Feb; 234(4):671-680. PubMed ID: 27988806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system effects of haloperidol on THC in healthy male volunteers.
    Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
    te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
    J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
    Jagannathan V; Venitz J
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biperiden Challenge Model in Healthy Elderly as Proof-of-Pharmacology Tool: A Randomized, Placebo-Controlled Trial.
    Bakker C; van Esdonk MJ; Stuurman RFE; Borghans LGJM; de Kam ML; van Gerven JMA; Groeneveld GJ
    J Clin Pharmacol; 2021 Nov; 61(11):1466-1478. PubMed ID: 34021607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.
    Ebert U; Siepmann M; Oertel R; Wesnes KA; Kirch W
    J Clin Pharmacol; 1998 Aug; 38(8):720-6. PubMed ID: 9725548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
    Renner UD; Oertel R; Kirch W
    Ther Drug Monit; 2005 Oct; 27(5):655-65. PubMed ID: 16175141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development.
    Hart EP; Alvarez-Jimenez R; Davidse E; Doll RJ; Cohen AF; Van Gerven JMA; Groeneveld GJ
    J Vis Exp; 2019 Feb; (144):. PubMed ID: 30799845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects.
    de Haas SL; Schoemaker RC; van Gerven JM; Hoever P; Cohen AF; Dingemanse J
    J Psychopharmacol; 2010 Nov; 24(11):1619-29. PubMed ID: 19648220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.